Importantly, epidemiological and clinical data suggest that COX-2 inhibitors reduce Alzheimer’s disease risk, and other age-related diseases, notably cancer (Ulrich et al., 2006; Vlad et al., 2008). The gene discussed is PTGS2; the disease is early-onset autosomal dominant Alzheimer disease.